Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

INO-3107

Vaccine (DNA plasmid) · Immune activation, directed at HPV-6 E6 protein, HPV-6 E7 protein and HPV-11 E6 protein · developed by INOVIO PHARMACEUTICALS

Phase 1/2 Most advanced trial (none active)

INO Developer

1 Registered trials

What is INO-3107?

INO-3107 is a DNA plasmid vaccine encoding HPV-6 and HPV-11 E6 and E7 proteins, administered by intramuscular electroporation. It elicits cytotoxic T-lymphocyte responses against tumor cells expressing these viral proteins. The vaccine is studied in recurrent respiratory papillomatosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (DNA plasmid)
Targets: HPV-6 E6 protein (antigen), HPV-6 E7 protein (antigen), HPV-11 E6 protein (antigen), HPV-11 E7 protein (antigen)
Mechanism: Immune activation, directed at HPV-6 E6 protein, HPV-6 E7 protein and HPV-11 E6 protein
Therapy area: Oncology, Respiratory
Developer: INOVIO PHARMACEUTICALS (INO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04398433	Phase 1/2	Respiratory Papillomatosis	Completed	INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Respiratory Papillomatosis

More from INOVIO PHARMACEUTICALS

DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Phase 1 INO-1400 Phase 1 INO-1401 Phase 1 INO-1800 Phase 1 INO-3106 Phase 1 INO-3401 Phase 1 INO-4201 Phase 1 INO-4202 Phase 1 INO-4212 Phase 1 INO-4500 Phase 1 INO-4700 Phase 2 INO-5401 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.

Follow INO, the company behind INO-3107

See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z